Periscope Capital’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Periscope Capital’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-485,500	Closed	-$65.2K	–	238
2024 Q4	$65.2K	Sell	485,500 -3,100	-0.6%	-$389	0.04%	79
2024 Q3	$57.2K	Hold	488,600	–	–	0.03%	86
2024 Q2	$58.9K	Sell	488,600 -418,400	-46%	-$57.2K	0.02%	132
2024 Q1	$130K	Hold	907,000	–	–	0.03%	146
2023 Q4	$159K	Hold	907,000	–	–	0.03%	180
2023 Q3	$209K	Buy	907,000 +588,600	+185%	+$116K	0.02%	248
2023 Q2	$60.9K	Buy	318,400 +85,400	+37%	+$14.9K	﹤0.01%	407
2023 Q1	$39.2K	Buy	+233,000	New	+$36.2K	﹤0.01%	567

Periscope Capital's BLACR Position: Q1 2025 in Review

Periscope Capital sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 485,500 shares — an estimated $65.2K sold.

Periscope Capital first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $209K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Periscope Capital reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Periscope Capital sold 485,500 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $65.2K.
Periscope Capital first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
Periscope Capital's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $209K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Periscope Capital's 13F filing for Q1 2025, filed 13 May 2025.